1526. Oral Fosfomycin Use for Urinary Tract Infections and its Clinical Impact on Hospital Stay
Session: Poster Abstract Session: Urinary Tract Infection
Friday, October 5, 2018
Room: S Poster Hall
Background: Oral fosfomycin is a treatment option for urinary tract infections (UTI) caused by multi-drug-resistant organisms (MDRO). The objective of the study was to describe the prescribing pattern of fosfomycin and determine its role in (1) preventing hospital admissions for patients seen in the emergency department or (2) promoting earlier discharges for admitted patients.

Methods: This retrospective chart review evaluated adults that received at least 1 dose of fosfomycin during the period 2014–2017. Information was collected using electronic medical records (e.g., demographics, symptoms, dose/duration of fosfomycin, urine culture results, length of stay, and hospital readmission). Statistical analysis was performed using descriptive statistics.

Results: 43 patients were included (60.5% females). Nearly half of the population (48.8%) had a history of recurrent UTIs. Patients received fosfomycin for cystitis (58.1%), pyelonephritis (34.9%), and asymptomatic bacteriuria (7%). Only 2 patients received greater than 1 dose. Empiric use of fosfomycin was seen in only 9.3%. Of those treated based on culture results, 84.6% of patients had MRDOs (29 ESBL, 2 VRE, 1 KPC, 1 resistant-Pseudomonas). No isolates had fosfomycin susceptibilities performed. In 72% of the time, patients had no other oral options. In 74.3% of the time, fosfomycin was used as step-down therapy from intravenous (IV) antibiotics (e.g., carbapenems 69%, ceftriaxone 13.8%). Infectious Diseases was consulted on 81.4% of cases. 7% of patients had documented allergies to the preferred agent. Treatment success was seen in 93% of patients, while 3 patients failed treatment requiring readmission for IV therapy. Fosfomycin use resulted in earlier discharge in 75.8% of cases (range of 1–6 days, mean 2.92 hospital days avoided per patient). For those who received fosfomycin as part of their emergency visit, 90% (9 of 10) were able to avoid hospitalization.

Conclusion: In our study, fosfomycin was used in UTI caused by MRDOs, with treatment successfully demonstrated in a majority of patients. Fosfomycin allowed for patients to avoid hospitalization or promoted earlier discharge, on average 3 days sooner than anticipated. Use of fosfomycin should be considered in appropriate patients in an effort to decrease length-of-stay or altogether avoid hospitalization.

Christina Mai, MD, Internal Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, Henry Donaghy, MD, Medicine - Infectious Diseases, Long Island Jewish Medical Center, New Hyde Park, NY and Thien-Ly Doan, PharmD, Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park, NY

Disclosures:

C. Mai, None

H. Donaghy, None

T. L. Doan, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.